NUDT18: A Potential Drug Target and Biomarker (G79873)

Target Name: NUDT18

NCBI ID: G79873

NUDT18

NUDT18: A Potential Drug Target and Biomarker

Nudix motif 18 (NUDT18) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. NUDT18 is a key regulator of gene expression and has been shown to play a role in various cellular processes, including cell growth, differentiation, and inflammation.

The discovery of NUDT18 as a potential drug target comes from a study by the researchers at the University of California, San Diego, led by Dr. J.P. Selimnia. The study, published in the journal Nature Medicine, identified NUDT18 as a potential drug target by using a technique called RNA-based assays to determine the effects of small molecules on NUDT18 levels.

The researchers found that NUDT18 was highly expressed in various tissues and was involved in the regulation of cellular processes, including cell growth, apoptosis, and inflammation. They also found that small molecules inhibited the activity of the NUDT18 enzyme, leading to the conclusion that NUDT18 could be a drug target.

In addition to its potential as a drug target, NUDT18 has also been identified as a potential biomarker. The researchers found that NUDT18 levels were elevated in various diseases, including cancer, and that the levels decreased in response to treatments. This suggests that NUDT18 could be used as a biomarker for disease diagnosis and treatment monitoring.

The identification of NUDT18 as a potential drug target and biomarker has important implications for the development of new treatments for various diseases. By targeting NUDT18, researchers may be able to develop new drugs or therapies that can treat diseases such as cancer, neurodegenerative diseases, and autoimmune disorders.

Furthermore, the study of NUDT18 also emphasizes the importance of using RNA-based assays to identify potential drug targets and biomarkers. RNA-based assays are becoming increasingly popular in the field of drug discovery, as they allow researchers to quickly and efficiently identify potential targets and biomarkers.

In conclusion, the study of NUDT18 has identified it as a potential drug target and biomarker, which has important implications for the development of new treatments for various diseases. Further research is needed to understand the full potential of NUDT18 as a drug target and biomarker, and to develop new treatments based on this discovery.

Protein Name: Nudix Hydrolase 18

Functions: Mediates the hydrolysis of oxidized nucleoside diphosphate derivatives. Hydrolyzes 8-oxo-7,8-dihydroguanine (8-oxo-Gua)-containing deoxyribo- and ribonucleoside diphosphates to the monophosphates. Hydrolyzes 8-oxo-dGDP and 8-oxo-GDP with the same efficiencies. Hydrolyzes also 8-OH-dADP and 2-OH-dADP. Exhibited no or minimal hydrolysis activity against 8-oxo-dGTP, 8-oxo-GTP, dGTP, GTP, dGDP and GDP. Probably removes oxidized guanine nucleotides from both the DNA and RNA precursor pools

The "NUDT18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUDT18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets